Blisibimod
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background Targeted, biologic inhibitors of B-cell Activating Factor (BAFF) have been evaluated in Phase 3 trials in over 5000…
Background We previously reported results of the 24-week phase IIb ADDRESS II study of atacicept, which demonstrated clinical…
Background Targeted, biologic inhibitors of B-cell Activating Factor (BAFF) have been evaluated in 4 large Phase 3 clinical…
Background Blisibimod (A-623, AMG 623), a potent and selective inhibitor of B-cell activating factor (BAFF), was evaluated in the…
Das Fusionsprotein Blisibimod wurde in einer internationalen doppelblinden Studie bei systemischem Lupus erythematosus (SLE) gepr…
In the last 50 years, only one drug has achieved marketing approval for treatment of systemic lupus erythematosus (SLE) by global…
Background Blisibimod, a peptibody that inhibits B-cell activating factor (BAFF), was previously found [1] to be safe…
Background Blisibimod is a peptibody that inhibits B-cell activating factor (BAFF). Significant improvements in secondary…
Background Blisibimod, a potent inhibitor of B cell activating factor (BAFF), was evaluated in a Phase 2b clinical trial in…
Background Elevations of BAFF are observed in patients with SLE. Here we report renal findings from a Phase 2b clinical trial in…